$314.46
0.70% yesterday
Nasdaq, May 13, 10:00 pm CET
ISIN
US45784P1012
Symbol
PODD

Insulet Corporation Stock price

$314.46
+58.99 23.09% 1M
+45.40 16.87% 6M
+53.39 20.45% YTD
+153.44 95.29% 1Y
+115.40 57.97% 3Y
+119.44 61.25% 5Y
+287.09 1,048.92% 10Y
Nasdaq, Closing price Tue, May 13 2025
-2.21 0.70%
ISIN
US45784P1012
Symbol
PODD
Sector

Key metrics

Market capitalization $22.28b
Enterprise Value $22.69b
P/E (TTM) P/E ratio 56.99
EV/FCF (TTM) EV/FCF 77.88
EV/Sales (TTM) EV/Sales 10.32
P/S ratio (TTM) P/S ratio 10.13
P/B ratio (TTM) P/B ratio 16.74
Revenue growth (TTM) Revenue growth 23.49%
Revenue (TTM) Revenue $2.20b
EBIT (operating result TTM) EBIT $340.80m
Free Cash Flow (TTM) Free Cash Flow $291.40m
Cash position $1.28b
EPS (TTM) EPS $5.56
P/E forward 80.01
P/S forward 8.84
EV/Sales forward 9.01
Short interest 4.80%
Show more

Is Insulet Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,793 stocks worldwide.

Insulet Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

27 Analysts have issued a Insulet Corporation forecast:

20x Buy
74%
7x Hold
26%

Analyst Opinions

27 Analysts have issued a Insulet Corporation forecast:

Buy
74%
Hold
26%

Financial data from Insulet Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
2,199 2,199
23% 23%
100%
- Direct Costs 635 635
16% 16%
29%
1,564 1,564
27% 27%
71%
- Selling and Administrative Expenses 901 901
28% 28%
41%
- Research and Development Expense 229 229
12% 12%
10%
434 434
34% 34%
20%
- Depreciation and Amortization 93 93
26% 26%
4%
EBIT (Operating Income) EBIT 341 341
37% 37%
15%
Net Profit 402 402
72% 72%
18%

In millions USD.

Don't miss a Thing! We will send you all news about Insulet Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Insulet Corporation Stock News

Neutral
Business Wire
about 14 hours ago
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, is proud to announce the publication of its 2024 Sustainability Report. This report underscores Insulet's unwavering commitment to sustainable practices and highlights significant achievements in environmental, soc...
Positive
Market Watch
one day ago
With U.S. economic growth turning negative during the first quarter, this earnings season's results might shed some light on which companies may best weather the disruption brought about by President Donald Trump's “liberation day” tariffs announced on April 2.
Positive
Investors Business Daily
3 days ago
Visa has topped a buy point, while fellow S&P 500 component Insulet gapped out of a base, leading five stocks on this weekend watchlist.
More Insulet Corporation News

Company Profile

Insulet Corp. is a medical device company. The firm engages in the development, manufacture and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Acton, MA.

Head office United States
CEO Ashley McEvoy
Employees 3,900
Founded 2000
Website www.insulet.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today